MACOP-B for advanced stage large cell lymphoma (DLCL). More is better?

L. Resegotti, U. Vitolo, M. Bertini, E. Brusamolino, B. Comotti, C. Tarella, G. Todeschini, M. Aglietta, T. Barbui, C. Bernasconi, R. Ghio, G. Perona, A. Pileri

Research output: Contribution to journalArticlepeer-review


A study of the predictive value for CR, DFS and OS of the presenting features was carried out on 180 patients with advanced stage DLCL treated with MACOP-B between June 1986 and March 1989. A multivariate regression analysis identified LDH level, bone marrow involvement and tumor burden as indipendent risk factors with a 4 year survival rate of 79%, 58% and 28% respectively. There-fore MACOP-B proved to be an adeguate treatment for the first two groups of patients but not for the third which requires a more aggressive treatment. A sequentil single drug high dose chemotherapy with collection of peripheral blood stem cell program followed by bone marrow harvesting, superintensive radio-chemotherapy and bone marrow transplant has been activated. Seven patients have been so far enrolled: preliminary results demonstrated the feasibility of the program. A larger number of cases and a longer follow-up is required for assessing the efficacy of this approach.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
Issue numberSUPPL. 1
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Hematology


Dive into the research topics of 'MACOP-B for advanced stage large cell lymphoma (DLCL). More is better?'. Together they form a unique fingerprint.

Cite this